
Releases
Virax Biolabs Raises $3.3 Million Through Preferred Option Exercise
London-based biotechnology firm Virax Biolabs Group Limited has secured $3.3 million in gross proceeds by incentivizing the immediate exercise of existing preferred investment options. The company lowered the exercise price from $10.00 to $6.00 per share to fast-track the capital infusion, which is expected to close by July 10, 2026.























